A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers

NCT05363592 PHASE1 COMPLETED

This is a randomized, open, single-dose, crossover-design, phase 1, single-center study to evaluate bioequivalence after co-administration of ALO and MET XR or administration of CT-L01 in healthy volunteers.

Details

Lead sponsor	Celltrion
Phase	PHASE1
Status	COMPLETED
Enrolment	48
Start date	Sat Jun 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Jul 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Healthy

Interventions

• CT-L01 12.5/500 mg
• Alogliptin Benzoate 12.5 mg
• Metformin HCl XR 500 mg

Countries

South Korea